Choi response criteria for prediction of survival in patients with metastatic renal cell carcinoma treated with anti-angiogenic therapies
Noemi Schmidt, Viviane Hess, Thomas Zumbrunn, Christian Rothermundt, Georg Bongartz & Silke Potthast
In mRCC, the Choi criteria separate prognostic groups better when compared with RECIST. This may allow early discrimination of patients benefiting from continued treatment. KEY POINTS : • CT is widely used to assess patients with metastatic renal cell carcinoma. • Various algorithms can be applied for tumour therapy control in patients with mRCC. • Follow-up should be based on evaluation of the tumour size and density. • RECIST is based only on tumour shrinkage and might lead to wrong conclusions.
|citation||Schmidt N, Hess V, Zumbrunn T, Rothermundt C, Bongartz G, Potthast S. Choi response criteria for prediction of survival in patients with metastatic renal cell carcinoma treated with anti-angiogenic therapies. Eur Radiol 2012; 23:632-9.|
|type||journal paper/review (English)|
|date of publishing||24-08-2012|
|journal title||Eur Radiol (23/3)|